p62 promotes proliferation, apoptosis‑resistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
05 2020
Historique:
received: 26 08 2019
accepted: 17 01 2020
pubmed: 24 4 2020
medline: 7 2 2021
entrez: 24 4 2020
Statut: ppublish

Résumé

Prostate cancer poses a public health threat to hundreds of people around the world. p62 has been identified as a tumor suppressor, however, the mechanism by which p62 promotes prostate cancer remains poorly understood. The present study aimed to investigate whether p62 promotes proliferation, apoptosis resistance and invasion of prostate cancer cells via the Kelch‑like ECH‑associated protein 1/nuclear factor erytheroid‑derived 2‑like 2/antioxidant response element (Keap1/Nrf2/ARE) axis. Immunohistochemical staining and immunoblotting were performed to determine the protein levels. Rates of proliferation, invasion and apoptosis of prostate cancer cells were assessed using an RTCA system and flow cytometric assays. Levels of reactive oxygen species (ROS) were assessed using Cell ROX Orange reagent and mRNA levels of Nrf2 target genes were detected by qRT‑PCR. It was revealed that p62 increased the levels and activities of Nrf2 by suppressing Keap1‑mediated proteasomal degradation in prostate cancer cells and tissues, and high levels of p62 promoted growth of prostate cancer through the Keap1/Nrf2/ARE system. Silencing of Nrf2 in DU145 cells overexpressing p62 led to decreases in the rate of cell proliferation and invasion and an increase in the rate of cell apoptosis. p62 activated the Nrf2 pathway, promoted the transcription of Nrf2‑mediated target genes and suppressed ROS in prostate cancer. Therefore, p62 promoted the development of prostate cancer by activating the Keap1/Nrf2/ARE pathway and decreasing p62 may provide a new strategy to ameliorate tumor aggressiveness and suppress tumorigenesis to improve clinical outcomes.

Identifiants

pubmed: 32323805
doi: 10.3892/or.2020.7527
pmc: PMC7107779
doi:

Substances chimiques

KEAP1 protein, human 0
Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0
NFE2L2 protein, human 0
Reactive Oxygen Species 0
SQSTM1 protein, human 0
Sequestosome-1 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1547-1557

Subventions

Organisme : NCI NIH HHS
ID : R01 CA142862
Pays : United States

Références

Mol Cell. 2013 Sep 12;51(5):618-31
pubmed: 24011591
Mol Cell Biol. 2004 Aug;24(16):7130-9
pubmed: 15282312
Biochem Soc Trans. 2015 Aug;43(4):687-9
pubmed: 26551713
Genes Cells. 2011 Feb;16(2):123-40
pubmed: 21251164
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
FASEB J. 2019 Jul;33(7):8022-8032
pubmed: 30913396
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13561-6
pubmed: 22872865
PLoS Genet. 2017 Mar 2;13(3):e1006593
pubmed: 28253260
Mol Carcinog. 2015 Oct;54(10):1194-204
pubmed: 25043940
Genes Dev. 2013 Oct 15;27(20):2179-91
pubmed: 24142871
Drug Metab Rev. 2006;38(4):769-89
pubmed: 17145701
Int J Oncol. 2014 Dec;45(6):2341-8
pubmed: 25269472
Nat Cell Biol. 2010 Mar;12(3):213-23
pubmed: 20173742
Cancer Cell. 2008 Apr;13(4):343-54
pubmed: 18394557
Cancer Cell. 2017 Nov 13;32(5):539-541
pubmed: 29136497
Cell. 2016 Oct 20;167(3):606-609
pubmed: 27768885
Int J Environ Res Public Health. 2019 Oct 07;16(19):
pubmed: 31591291
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
Cell Death Dis. 2017 Jun 15;8(6):e2876
pubmed: 28617433
Photochem Photobiol. 2018 May;94(3):432-437
pubmed: 28715145
CA Cancer J Clin. 2016 Jul;66(4):290-308
pubmed: 26910411
Biochem J. 1996 Jan 1;313 ( Pt 1):17-29
pubmed: 8546679
Cancer Cell. 2018 Apr 9;33(4):770-784.e6
pubmed: 29634950
Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70
pubmed: 18838122
Free Radic Biol Med. 2015 Nov;88(Pt B):93-100
pubmed: 26117331
Prostate. 2018 Apr;78(5):390-400
pubmed: 29368435
Cancer. 2014 Apr 15;120(8):1228-36
pubmed: 24390809
Cell Metab. 2008 Oct;8(4):325-32
pubmed: 18840363
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Mol Cell. 2012 Oct 26;48(2):158-67
pubmed: 23102266
J Cell Biol. 2011 Apr 18;193(2):275-84
pubmed: 21482715
Trends Biochem Sci. 2012 Jun;37(6):230-6
pubmed: 22424619
J Biol Chem. 2003 Jun 13;278(24):21592-600
pubmed: 12682069
Mol Cell Biol. 2005 Jan;25(1):162-71
pubmed: 15601839
Mol Cell Biol. 2010 Jul;30(13):3275-85
pubmed: 20421418
Cell Metab. 2006 Mar;3(3):211-22
pubmed: 16517408
J Biol Chem. 2010 Jul 16;285(29):22576-91
pubmed: 20452972
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Redox Biol. 2013 Jan 18;1:45-9
pubmed: 24024136
Prostate. 2018 May;78(6):426-434
pubmed: 29383752
Mol Cell Biol. 1998 May;18(5):3069-80
pubmed: 9566925

Auteurs

Ganggang Jiang (G)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Xue Liang (X)

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Yiqiao Huang (Y)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Ziquan Lan (Z)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Zhiming Zhang (Z)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Zhengming Su (Z)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Zhiyuan Fang (Z)

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Yuxiong Lai (Y)

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Wenxia Yao (W)

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Ting Liu (T)

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

La Hu

Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Fen Wang (F)

Center for Translational Cancer Research, Texas A&M Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.

Hai Huang (H)

Department of Urology, The Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou 510120, P.R. China.

Leyuan Liu (L)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Xianhan Jiang (X)

Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH